U.S. approves 2nd Alzheimer's drug to modestly slow disease

4 months ago 3
ARTICLE AD BOX
A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis in 2017.

The U.S. Food and Drug Administration gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.

Read Entire Article